New antiarrhythmic drugs for the treatment of atrial fibrillation

Herz

Volumn 33, Issue 8, 2008, Pages 562-567

  Schmitt, Jörn ^c   Ehrlich, Joachim R ^c   Hohnloser, Stefan H ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c NONE

Author keywords

Atrial fibrillation; Atrial selective drugs; Dronedarone; Vernakalant

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CONNEXIN 40; CONNEXIN 43; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRONEDARONE; INWARDLY RECTIFYING POTASSIUM CHANNEL; PLACEBO; POTASSIUM CHANNEL; SOTALOL; VERNAKALANT;

ARTICLE; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSGEUSIA; FIRST PASS EFFECT; GERIATRIC PATIENT; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HUMAN; LUNG TOXICITY; PROTEIN EXPRESSION; PROTEIN TARGETING; SIDE EFFECT; SINUS RHYTHM; SKIN TOXICITY; SNEEZING; SODIUM CURRENT; THYROID DISEASE; TORSADE DES POINTES; TREATMENT DURATION;

ANTI-ASTHMATIC AGENTS; ATRIAL FIBRILLATION; GERMANY; HUMANS; PRACTICE GUIDELINES AS TOPIC; QUALITY ASSURANCE, HEALTH CARE;

EID: 58449112149     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-008-3151-z     Document Type: Article

References (38)

1. R.T. Greenlee H. Vidaillet 2005 Recent progress in the epidemiology of atrial fibrillation Curr Opin Cardiol 20 7 14
2. W.M. Feinberg J.L. Blackshear A. Laupacis 1995 Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications Arch Intern Med 155 469 473
3. E.J. Benjamin P.A. Wolf R.B. D'Agostino 1998 Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 946 952
4. Y. Miyasaka M.E. Barnes K.R. Bailey 2007 Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study J Am Coll Cardiol 49 986 992
5. S.H. Hohnloser K.H. Kuck J. Lilienthal 2000 Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial Lancet 356 1789 1794
6. I.C. Van Gelder V.E. Hagens H.A. Bosker 2002 Rate Controlversus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation N Engl J Med 347 1834 1840
7. D.G. Wyse A.L. Waldo J.P. DiMarco 2002 Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 1825 1833
8. D. Roy M. Talajic S. Nattel 2008 Rhythm control versus rate control for atrial fibrillation and heart failure N Engl J Med 358 2667 2677
9. J. Kneller J. Kalifa R. Zou 2005 Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model Circ Res 96 e35 e47
10. D. Roy M. Talajic P. Dorian 2000 Amiodarone to preventrecurrence of atrial fibrillation N Engl J Med 342 913 920
11. S.H. Hohnloser B.N. Singh 1995 Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications J Cardiovasc Electrophysiol 6 920 936
12. + channel proteins Kir3.1 and Kir3.4 in the ventricle, atrium, and sinoatrial node of heart J Histochem Cytochem 49 1221 1234
13. F. Atienza J. Almendral J. Moreno 2006 Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism Circulation 114 2434 2442
14. 4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials Circulation 104 2551 2557
15. J.R. Ehrlich T.J. Cha L. Zhang 2004 Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium J Physiol 557 583 597
16. J.R. Ehrlich P. Biliczki S.H. Hohnloser 2008 Atrial-selective approaches for the treatment of atrial fibrillation J Am Coll Cardiol 51 787 792
17. + channel protein in explanted cardiac tissue J Clin Invest 96 282 292
18. S. Nattel L. Yue Z. Wang 1999 Cardiacultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity Cell Physiol Biochem 9 217 226
19. + current densities and Kv1.5 expression are reduced in chronicatrial fibrillation Circ Res 80 772 781
20. A.J. Workman K.A. Kane A.C. Rankin 2001 The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronicatrial fibrillation Cardiovasc Res 52 226 235
21. Kur in controlling action potential shape and contractility in the human atrium: influence of chronicatrial fibrillation Circulation 110 2299 2306
22. J.R. Ehrlich H. Ocholla H. Rütten 2008 Characterization of AVE1231 block of the human ultrarapid delayed rectifier, Kv1.5 J Cardiovasc Pharmacol 51 380 387
23. Kur promote atrial fibrillation? Heart Rhythm 5 1304 1309
24. H.M. Van der Velden J. Ausma M.B. Rook 2000 Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat Cardiovasc Res 46 476 486
25. M.H. Gollob D.L. Jones A.D. Krahn 2006 Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation N Engl J Med 354 2677 2688
26. S. Nattel L. Carlsson 2006 Innovative approaches to anti-arrhythmic drug therapy Nat Rev Drug Discov 5 1034 1049
27. D. Fedida 2007 Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent Expert Opin Investig Drugs 16 519 532
28. D. Fedida P.M. Orth J.Y. Chen 2005 The mechanism of atrial antiarrhythmic action of RSD1235 J Cardiovasc Electrophysiol 16 1227 1238
29. Na and suppresses early after depolarizations and torsades de pointes induced by class III agents Cardiovasc Res 70 486 496
30. D. Roy B.H. Rowe I.G. Stiell 2004 A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation J Am Coll Cardiol 44 2355 2361
31. D. Roy C.M. Pratt C. Torp-Pedersen 2008 Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial Circulation 117 1518 1525
32. F.T. Wegener J.R. Ehrlich S.H. Hohnloser 2006 Dronedarone: an emerging agent with rhythm- and rate-controlling effects J Cardiovasc Electrophysiol 17 Suppl2 S17 S20
33. W. Sun J.S.M. Sarma B.N. Singh 1999 Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative in the rabbit heart. Comparison with amiodarone Circulation 100 2276 2283
34. W. Sun J.S.M. Sarma B.N. Singh 2002 Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone J Cardiovasc Pharmacol 39 677 684
35. P. Touboul J. Brugada A. Capucci 2003 Dronedarone for prevention of atrial fibrillation: a dose-ranging study Eur Heart J 24 1481 1487
36. B.N. Singh S.J. Connolly H.J. Crijns 2007 Dronedarone for maintenance of sinus rhythmin atrial fibrillation or flutter N Engl J Med 357 987 999
37. L. Kober C. Torp-Pedersen J.J.V. McMurray 2008 Increased mortality after dronedarone therapy for severe heart failure N Engl J Med 358 2678 2687
38. S.H. Hohnloser S.J. Connolly H.J. Crijns 2008 Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter J Cardiovasc Electrophysiol 19 69 73